SAP Testing the Waters, BYD On the Offensive, and MustGrow Biologics Raises Fresh Capital - Is a Rebound on the Horizon?

SAP Is Desperately Searching for a Bottom

SAP, Europe's flagship software company and once the undisputed leader, has lost significant ground in recent months. From its impressive record high of EUR 283.50 in February 2025, the price has since slipped to just over EUR 130. That represents a steep decline of over 50%. The reasons for this sell-off are manifold, but cannot be dismissed. Perhaps the sell-off is already a bit exaggerated, but it could become even more so in the coming weeks—who knows? For one thing, the uncertain trend in chip prices is making investors nervous. Hardware costs for cloud infrastructures could rise, as contract manufacturers like TSMC have announced price increases.

In addition, concerns about the future surrounding the rapid spread of artificial intelligence (AI) are weighing on the entire software sector. Many investors simply fear that established solutions could be displaced by new AI tools.

Meanwhile, there is absolute radio silence on the operational front. The company is in the so-called "quiet period" ahead of its quarterly earnings report on July 23. Analysts see significant potential again at the current discounted level. Although the research firm Jefferies lowered its price target to EUR 210, it clearly maintains its "Buy" rating. Long-term glimmers of hope, such as a planned EU tax reform, could also save the complexly structured group billions in the future. Nevertheless, the technical picture remains severely weakened for the time being. From a technical analysis perspective, it is even possible that the stock could slide toward EUR 120—or, in an extreme scenario, even toward EUR 100. Nothing can be ruled out during such a market phase. Investors who believe in SAP's future—even amid AI—could enter the market in stages as prices continue to fall. Very exciting!

BYD Makes a Push in Europe, but the Market Reacts Coolly

From SAP's virtual data cloud, we now shift to the real world of vehicles on the road, as the Chinese EV group BYD is also currently facing a tough time on the stock market. Shares are languishing on European exchanges near their 52-week low, hovering around the EUR 8.50 mark. In fact, it is not far from the all-time low of EUR 7.62 set in August 2024. Yet the company is posting rather impressive operating figures. In May 2026, BYD sold over 160,000 vehicles outside of China, setting an all-time record.

Nevertheless, the European Union's impending tariff policy on plug-in hybrids is significantly dampening investor sentiment. The automaker, however, is not particularly deterred by this and is planning a massive model offensive. At the British Goodwood Festival of Speed, BYD is making a major impact, unveiling no fewer than eight new models for the European market. These include not only vehicles for the mass market but also the premium brand Denza and the luxury segment Yangwang. In addition, the Shark pickup fills an important gap in Europe. Strategically, BYD is doing almost everything right, but the significant first-quarter profit decline and the relentless price war in its home market of China continue to keep stock market investors cautious. A clear breakout has yet to materialize. Nevertheless, at the EUR 8 to 8.50 level, the stock becomes attractive for a rebound trade. The RSI has reached 20 and is already signaling that an upward correction toward EUR 10 could occur soon.

MustGrow Biologics: Fresh Capital and Positioned for a Potential Breakout

While billion-dollar stocks such as SAP and BYD are battling strong headwinds in some cases, an interesting development is emerging in the Canadian province of Saskatchewan. MustGrow Biologics specializes in sustainable agricultural technology—an area considered critical for the future, given the steadily growing global population and rising food demand. The company uses patented technologies to derive natural biopesticides and organic fertilizers from the mustard plant. At a time when synthetic agricultural fertilizers and chemicals are increasingly subject to regulatory pressure, MustGrow's core products, TerraSante and TerraMG, which is pre-registered, are perfectly in tune with the spirit of the times.

The latest news underscores the company's strong fundamental performance. In May 2026, the mustard-derived organic biofertility product TerraSante received registration in additional key US agricultural states. This opens up access to major markets for high-value crops. This expansion is supported by strong strategic partners. In the key EMEA market for biological crop protection, MustGrow is working exclusively with industry leader Bayer, which is estimated to invest USD 35 to 40 million in development and commercialization efforts.

https://youtu.be/Y0CvferI6Cs

In June 2026, management delivered another major milestone. The company successfully closed its non-brokered LIFE private placement, issuing approximately 7.48 million shares at a price of CAD 0.50 per unit, and raising gross proceeds of roughly CAD 3.74 million. In addition to the common shares, the units include a warrant entitling buyers to purchase one additional share for CAD 0.70 over the next five years. This fresh capital is expected to be used to expand TerraSante production and support general working capital requirements. The capital structure remains relatively lean, with approximately 70.4 million shares outstanding. At a market capitalization of around CAD 30 million, the company still appears to offer considerable room for growth.

From a technical analysis perspective, the setup at MustGrow Biologics appears increasingly attractive. The stock has reached the lower boundary of its trend channel at approximately CAD 0.40 to 0.41 (see chart below), an area that represents significant support. This could provide the foundation for renewed upward momentum. Following the successful financing and with fresh capital behind it, the shares may well be positioned for a rebound. Initial upside targets of CAD 0.50, or even CAD 0.60, are therefore back in focus. Should the stock successfully break through these levels, a move toward the CAD 0.75 to 0.80 range cannot be ruled out from a technical perspective, as this corresponds to the most recent significant high. At current levels, the risk-reward profile appears favourable for investors considering an entry position.

In summary, the market currently shows little, if any, tolerance for major missteps. SAP must prove with its operating figures at the end of July that margins are holding steady and the cloud narrative remains intact. Until then, anything is possible. On the downside, investors who believe in the long-term prospects of the software giant may consider building a position gradually during periods of weakness.

At BYD, global expansion plans face fierce domestic price competition and regulatory hurdles in Europe. The company is growing, but the market demands significantly higher profitability. At EUR 8–8.50, bold investors could buy the stock for a rebound trade, targeting EUR 10.

The current situation at MustGrow Biologics appears increasingly attractive following the recent share price weakness. The company operates in a promising long-term growth market, continues to secure key regulatory approvals, and has successfully strengthened its financial position. With Bayer as a strong strategic partner and the stock trading near the lower end of its long-term trend channel, MustGrow has established a compelling starting position. For informed investors with a higher risk tolerance, the stock may warrant a closer look at current levels.